Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2009

01-06-2009 | Review

Hospital infections, animal models and alternatives

Authors: R. Seabra, N. Bhogal

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2009

Login to get access

Abstract

Bacteria represent a threat to human health, especially in healthcare settings, and treatment options are limited due to increasingly common antibiotic resistance. It is, therefore, imperative that we continue to investigate the mechanisms of pathogenesis and host-pathogen interactions. Despite the fact that some bacterial pathogens are capable of infecting both humans and at least one laboratory animal species, the relevance and animal welfare implications of animal infection models are of concern. Here, we consider whether plants and lower organisms are suitable candidates to investigate certain aspects of bacterial pathogenicity. Indeed, many of the virulence factors employed by micro-organisms render the capacity to infect a range of hosts. The scope for using such models, together with 3D human “organoids”, to accelerate the development and screening of novel drugs and treatment combinations for bacterial infections is considered.
Literature
2.
go back to reference European Centre for Disease Prevention and Control (2007) Report on the status of communicable diseases in the EU and EEA/EFTA countries. In: Annual epidemiological report on communicable diseases in Europe. http://www.epha.org/a/2656 Accessed 04 May 2008 European Centre for Disease Prevention and Control (2007) Report on the status of communicable diseases in the EU and EEA/EFTA countries. In: Annual epidemiological report on communicable diseases in Europe. http://​www.​epha.​org/​a/​2656 Accessed 04 May 2008
4.
go back to reference Payne DJ, Gwynn MN, Holmes DJ et al (2008) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40. doi:10.1038/nrd2201 CrossRef Payne DJ, Gwynn MN, Holmes DJ et al (2008) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29–40. doi:10.​1038/​nrd2201 CrossRef
5.
go back to reference Cash HA, Woods DE, McCullough B et al (1979) A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 119:453–459PubMed Cash HA, Woods DE, McCullough B et al (1979) A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 119:453–459PubMed
9.
10.
go back to reference Mikuniya T, Kato Y, Ida T et al (2007) Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 13:285–290. doi:10.1007/s10156-007-0534-7 PubMedCrossRef Mikuniya T, Kato Y, Ida T et al (2007) Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 13:285–290. doi:10.​1007/​s10156-007-0534-7 PubMedCrossRef
12.
13.
go back to reference Silo-Suh L, Suh SJ, Sokol PA et al (2002) A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis. Proc Natl Acad Sci USA 99:15699–15704. doi:10.1073/pnas.242343999 PubMedCrossRef Silo-Suh L, Suh SJ, Sokol PA et al (2002) A simple alfalfa seedling infection model for Pseudomonas aeruginosa strains associated with cystic fibrosis shows AlgT (sigma-22) and RhlR contribute to pathogenesis. Proc Natl Acad Sci USA 99:15699–15704. doi:10.​1073/​pnas.​242343999 PubMedCrossRef
15.
go back to reference He J, Baldini RL, Déziel E et al (2004) The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci USA 101:2530–2535. doi:10.1073/pnas.0304622101 PubMedCrossRef He J, Baldini RL, Déziel E et al (2004) The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci USA 101:2530–2535. doi:10.​1073/​pnas.​0304622101 PubMedCrossRef
24.
go back to reference Windhorst S, Frank E, Georgieva DN et al (2002) The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia: characterization of the protein and molecular cloning of the gene. J Biol Chem 277:11042–11049. doi:10.1074/jbc.M109525200 PubMedCrossRef Windhorst S, Frank E, Georgieva DN et al (2002) The major extracellular protease of the nosocomial pathogen Stenotrophomonas maltophilia: characterization of the protein and molecular cloning of the gene. J Biol Chem 277:11042–11049. doi:10.​1074/​jbc.​M109525200 PubMedCrossRef
25.
go back to reference Apidianakis Y, Mindrinos MN, Xiao W et al (2005) Profiling early infection responses: Pseudomonas aeruginosa eludes host defenses by suppressing antimicrobial peptide gene expression. Proc Natl Acad Sci USA 102:2573–2578. doi:10.1073/pnas.0409588102 PubMedCrossRef Apidianakis Y, Mindrinos MN, Xiao W et al (2005) Profiling early infection responses: Pseudomonas aeruginosa eludes host defenses by suppressing antimicrobial peptide gene expression. Proc Natl Acad Sci USA 102:2573–2578. doi:10.​1073/​pnas.​0409588102 PubMedCrossRef
27.
go back to reference Lutter EI, Faria MM, Rabin HR et al (2008) Pseudomonas aeruginosa cystic fibrosis isolates from individual patients demonstrate a range of levels of lethality in two Drosophila melanogaster infection models. Infect Immun 76:1877–1888. doi:10.1128/IAI.01165-07 PubMedCrossRef Lutter EI, Faria MM, Rabin HR et al (2008) Pseudomonas aeruginosa cystic fibrosis isolates from individual patients demonstrate a range of levels of lethality in two Drosophila melanogaster infection models. Infect Immun 76:1877–1888. doi:10.​1128/​IAI.​01165-07 PubMedCrossRef
38.
go back to reference Gaonkar TA, Modak SM (2003) Comparison of microbial adherence to antiseptic and antibiotic central venous catheters using a novel agar subcutaneous infection model. J Antimicrob Chemother 52:389–396. doi:10.1093/jac/dkg361 PubMedCrossRef Gaonkar TA, Modak SM (2003) Comparison of microbial adherence to antiseptic and antibiotic central venous catheters using a novel agar subcutaneous infection model. J Antimicrob Chemother 52:389–396. doi:10.​1093/​jac/​dkg361 PubMedCrossRef
42.
go back to reference Freeman J, O’Neill FJ, Wilcox MH (2003) Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 52:96–102. doi:10.1093/jac/dkg267 PubMedCrossRef Freeman J, O’Neill FJ, Wilcox MH (2003) Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 52:96–102. doi:10.​1093/​jac/​dkg267 PubMedCrossRef
45.
Metadata
Title
Hospital infections, animal models and alternatives
Authors
R. Seabra
N. Bhogal
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2009
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0680-6

Other articles of this Issue 6/2009

European Journal of Clinical Microbiology & Infectious Diseases 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.